Tendons and early studies
BPC-157 contains fifteen amino acids. Its origin does not make it an established human medicine. The substance investigated in experiments is made by chemical synthesis, and its relationship to a stomach-juice protein does not establish that another route of exposure is safe.
In a 2003 experiment involving cut Achilles tendons in rats, BPC-157 improved mechanical, functional, and tissue measurements of healing. The Achilles connects the calf to the heel. Testing the repaired tendon's strength gives useful detail beyond a photograph of tissue alone.
The experiment still concerned a particular injury in rats. It cannot establish how a person's tendon will heal or how soon normal activity can resume. A result can justify further investigation without supporting a treatment claim. That distinction is especially important when the same paper appears beside broad claims about sports recovery.
Blood vessels and the gut
Researchers have linked BPC-157 to angiogenesis, the formation of new blood vessels. Experiments involving vessel-lining cells, chick membranes, and rat muscle investigated a signaling receptor called VEGFR2. The results suggest a possible pathway through which the peptide influences repair in those models.
A possible mechanism does not establish a complete account of how the substance acts in people. A pathway can behave differently across tissues, species, and injury settings. The relationship between a laboratory signal and a meaningful recovery outcome needs to be measured rather than assumed.
The stomach-related literature includes gastric-ulcer experiments in rats. Those findings help explain why BPC-157 appears in discussions about the gut. They do not establish a treatment for a person's digestive symptoms or show that tendon and gut effects can be expected together.
What has been observed in people
A 2025 intravenous safety pilot involved two healthy adults. The report described no observed adverse events or meaningful changes in the measured health markers. It examined short-term tolerability, not healing of an injury. Two people cannot provide reliable reassurance about uncommon or delayed harms.
The 2025 narrative review of musculoskeletal evidence describes a record dominated by animal work with only small human reports. Its findings need to be understood within that review's scope and date. The human observations do not establish a general benefit for injured people.
A comparison group matters because discomfort and function can change over time without the tested substance. Other care and expectations also affect an uncontrolled report. A published account is evidence that observations were reported; it is not automatically evidence that the intervention caused the change.
Safety questions that remain
The limited human record leaves uncertainty about interactions, pregnancy, prolonged exposure, and rare reactions. BPC-157 has no FDA-approved therapeutic use. There is no approved product label supplying a validated dosing schedule or a complete list of contraindications for these uses.
FDA's 2026 review of BPC-157 discusses the possibility of immune reactions and difficulties characterizing peptide impurities. A reaction may relate to the peptide, its chemical form, or unwanted material in a preparation. A purity percentage by itself cannot answer all of those questions.
Because vessel growth is part of the proposed mechanism, unwanted growth is also a theoretical concern. This is not evidence that BPC-157 causes cancer. It is an unresolved question that small, short observations cannot settle. The broader sports-medicine review places the shortage of rigorous human safety data alongside the encouraging animal findings.
FDA status and practical questions
BPC-157 appears in the withdrawn-nomination group on FDA's safety-risk page, current as of April 22, 2026. It is not in that page's current Category 2 table. Withdrawal means the nomination was taken back; it does not mean FDA cleared the substance or approved it for compounding.
Questions about a proposed treatment include which chemical form is involved, what human evidence addresses the actual condition, and what quality checks apply. No animal amount can establish a personal dose. The comparison page places the tendon work beside studies of the other compounds without treating them as interchangeable.